Beta Drugs Limited issued a clarification to the National Stock Exchange regarding observations on a corrigendum to the Extraordinary General Meeting notice.
The disclosure includes a detailed shareholding pattern before and after a proposed preferential issue of equity shares.
Post-issue, promoter holding dilutes from 64.63% to 59.10%, while institutional holding rises from 3.43% to 9.14%.